Ratio Therapeutics
Ratio Therapeutics, Inc.
Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. Innovative Technologies R
ratiotx.com · Boston, MA
Funding event
The round itself, as filedInferred stageSeries C+
Sold of offered$70.0M of $70.0M
Filed2026-07-31
Days since filing65
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-07-16
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- John W. HoppinExecutive Officer · Director
- John BabichDirector
- Marc BeckerExecutive Officer
- Scott MacDonaldExecutive Officer
- William CowanDirector
- Susan WhoriskeyDirector
- Albert HolmanDirector
- Allan GreenDirector
- Brandon IngersollDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged100% sold2.6 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-230
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.